Looks some good info came out of Phase II trials on Byetta. Analysts seemed pro and con:
Byetta LAR is "a game changer with a multi-billion potential," says Mark Schoenebaum, of Bear Stearns, who raised his rating for Amylin on Tuesday to outperform from peer perform.
"The primary criticism of the data will be the small sample size and lack of longer-term follow-up," he says in a research report. Despite the small sample, the results are "highly compelling."
It was also interesting how some people lost weight with the drug:
The drug group had an average weight loss of 9 pounds vs. the placebo group. The nausea rate for the drug group was 20% vs. 7% for the placebo group.
Hmm, this would be a good deal for the Type 2 diabetes people who are overweight. They lower their blood sugar levels and lose some weight so they won't be at risk of other obesity related illnesses.
No comments:
Post a Comment